Formidable Asset Management LLC Sells 3,487 Shares of Chemed Corporation $CHE

Formidable Asset Management LLC cut its holdings in shares of Chemed Corporation (NYSE:CHE) by 17.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,781 shares of the company’s stock after selling 3,487 shares during the quarter. Chemed accounts for approximately 1.1% of Formidable Asset Management LLC’s holdings, making the stock its 16th biggest holding. Formidable Asset Management LLC’s holdings in Chemed were worth $7,487,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in CHE. JPMorgan Chase & Co. boosted its stake in shares of Chemed by 122.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 499,968 shares of the company’s stock valued at $223,856,000 after purchasing an additional 275,423 shares in the last quarter. Norges Bank purchased a new position in Chemed in the 2nd quarter worth $89,388,000. AQR Capital Management LLC raised its position in Chemed by 160.9% in the 2nd quarter. AQR Capital Management LLC now owns 201,041 shares of the company’s stock worth $97,893,000 after purchasing an additional 123,982 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Chemed by 740.9% in the third quarter. Arrowstreet Capital Limited Partnership now owns 95,573 shares of the company’s stock worth $42,792,000 after purchasing an additional 84,208 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its position in Chemed by 29.4% during the third quarter. Epoch Investment Partners Inc. now owns 307,275 shares of the company’s stock valued at $137,579,000 after buying an additional 69,878 shares during the period. 95.85% of the stock is currently owned by institutional investors.

Chemed Stock Performance

NYSE CHE opened at $380.46 on Friday. The stock has a market cap of $5.24 billion, a P/E ratio of 20.71, a price-to-earnings-growth ratio of 1.50 and a beta of 0.49. Chemed Corporation has a fifty-two week low of $365.20 and a fifty-two week high of $623.60. The stock has a 50 day simple moving average of $422.33 and a two-hundred day simple moving average of $433.38.

Chemed (NYSE:CHE) last announced its earnings results on Wednesday, February 25th. The company reported $6.42 EPS for the quarter, missing analysts’ consensus estimates of $7.02 by ($0.60). The business had revenue of $639.34 million for the quarter, compared to the consensus estimate of $659.09 million. Chemed had a net margin of 10.48% and a return on equity of 25.66%. Chemed’s revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.83 EPS. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. Sell-side analysts predict that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 13th. Investors of record on Monday, February 23rd were given a dividend of $0.60 per share. The ex-dividend date was Monday, February 23rd. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. Chemed’s payout ratio is currently 13.06%.

Insider Transactions at Chemed

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $403.18, for a total value of $806,360.00. Following the completion of the transaction, the chief executive officer directly owned 93,719 shares of the company’s stock, valued at $37,785,626.42. This represents a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Zacks Research cut Chemed from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 4th. Oppenheimer reduced their price target on Chemed from $580.00 to $500.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Jefferies Financial Group downgraded Chemed from a “buy” rating to a “hold” rating in a research report on Thursday, January 22nd. Royal Bank Of Canada reissued a “sector perform” rating and set a $422.00 price objective (down from $572.00) on shares of Chemed in a research note on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $498.00.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.